[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Pivotal Study of the SonoMotion Break Wave™ (Trade Mark) System for the Comminution of Urinary Tract Stones


Description

The goal of this clinical trial is to test the Break Wave™ system in patients with upper urinary tract stones. The main question it aims to answer is whether the device is safe and effective in fragmenting (breaking) stones. Participants will a) undergo the Break Wave™ procedure, b) have a telehealth visit at 2 weeks, and c) return for an imaging study at approximately 10 weeks post-procedure.This is a prospective, open-label, multi-center, single-arm (non-randomized) study to demonstrate the safety and effectiveness of breaking stones in the upper urinary tract using the SonoMotion Break Wave™ technology. Up to 116 patients will be screened to participate. Depending on the institution, the procedure may be performed in an outpatient hospital surgical environment, or in a non-surgical environment such as a clinic or office procedure room. Subjects will have a target stone diagnosed to be \>4millimeter (mm) to 10 mm in size. Safety will be measured by the adverse event occurrence, unp

Trial Eligibility

Inclusion Criteria: 1. Subjects presenting with at least one stone apparent on radiographic imaging. 2. Target stone must be within the upper urinary tract. 3. Target stone is indicated for shock wave lithotripsy (SWL) treatment per American Urological Association (AUA) 2016 guidelines. 4. Target stone size is \> 4 mm and ≤ 10 mm. 5. Subject is willing and able to provide informed consent and comply with the study protocol required follow up visits. 6. Target stone can be individually visualized from other stones. Exclusion Criteria: 1. Subject has an acute untreated urinary tract infection or urosepsis. 2. Subject has an uncorrected bleeding disorder or coagulation abnormality. 3. Subject is confirmed to be or suspected to be pregnant. 4. Subject has a urinary tract obstruction distal to the stone. 5. Subject is receiving anticoagulants and is unable or not willing to cease the medication for the Break Wave procedure 6. Subject has stones that are not echogenically visible with ultrasound. 7. Subject belongs to a vulnerable group (prisoner, etc.). 8. Patients unwilling to comply with the follow-up protocol, including post-procedure radiographic imaging. 9. Subject is under 18 years of age. 10. Subject's anatomy limits ability to focus on or deliver Break Wave to the target stone (e.g. viable acoustic window). 11. Subject has a calcified abdominal aortic aneurysm or calcified renal artery aneurysms. 12. Subject has a solitary kidney. 13. Subject has a comorbidity risk(s) which, at the discretion of the physician, would make the subject a poor candidate for the Break Wave procedure, such as anatomical anomalies that may not be conducive to adequate stone fragment passage. 14. Subject is unable to read or comprehend the consent form.

Study Info

Organization

SonoMotion


Primary Outcome

Primary Effectiveness Endpoint


Outcome Timeframe 10 +/- 2 weeks post final Break Wave procedure

NCTID NCT05701098

Phases NA

Primary Purpose TREATMENT

Start Date 2023-10-09

Completion Date 2024-12

Enrollment Target 116

Interventions

DEVICE Break Wave extracorporeal lithotripsy

Locations Recruiting

University of California- San Diego

United States, California, San Diego


University of California - San Francisco

United States, California, San Francisco


Kaiser Permanente

United States, California, Santa Clara


Northwestern Medicine

United States, Illinois, Chicago


Lehigh Valley Health Network

United States, Pennsylvania, Allentown


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Kidney Disease delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.